Brown K J, Vesey B V, Tannock G W, Bell E B, Lines D R, Elliott R B
Med Microbiol Immunol. 1980 Feb;168(1):11-24. doi: 10.1007/BF02121648.
Faecal samples were taken from three diet-managed phenylketonuric children to determine effects of beta-2-thienylalanine (beta-2-t) on indigenous bacteria. From sample swabs, 127 anaerobes were identified and tested for beta-2-t inhibition on a phenylalanine (Phe)-free medium, Anaerobe Inhibition Test (AIT) agar. Of the isolates, 77.9% grew sufficiently to assay reactions on at least 25% of AIT plates. Using Phe-containing Columbia agar, 86.5% of the strains could be assayed. None of 28 Bacteroides cultures was inhibited by beta-2-t on AIT. Of the genera, Bifidobacterium, Eubacterium, Lactobacillus, Peptostreptococcus, and Propionibacterium, no isolates which would grow on AIT were inhibited. At least one isolate of each of the genera Peptococcus, Fusobacterium, and Clostridium was inhibited. Of 127 total isolates, only nine were inhibited by beta-2-t on AIT, and inhibition was abolished on Columbia agar. Thirty-nine "aerobes" were isolated from the same patients. Strains of the genera tested reacted similarly to previously tested strains from non-PKU sources. Also, anaerobically isolated Excherichia coli were inhibited, while Streptococcus faecalis cultures were not, confirming results on aerobically-isolated non-PKU cultures of the same species. These studies, the first dealing with beta-2-t and anaerobic bacteria, suggest that little change in intestinal bacterial populations might be expected during in vivo beta-2-t treatment.
采集了三名接受饮食管理的苯丙酮尿症儿童的粪便样本,以确定β-2-噻吩丙氨酸(β-2-t)对肠道细菌的影响。从样本拭子中,鉴定出127株厌氧菌,并在无苯丙氨酸(Phe)的培养基——厌氧菌抑制试验(AIT)琼脂上测试其对β-2-t的抑制作用。在分离出的菌株中,77.9%生长良好,足以在至少25%的AIT平板上检测反应。使用含Phe的哥伦比亚琼脂,86.5%的菌株可以进行检测。28株拟杆菌培养物在AIT上均未被β-2-t抑制。在双歧杆菌属、真杆菌属、乳杆菌属、消化链球菌属和丙酸杆菌属中,没有在AIT上生长的分离株受到抑制。消化球菌属、梭杆菌属和梭菌属中至少各有一株分离株受到抑制。在总共127株分离株中,只有9株在AIT上被β-2-t抑制,而在哥伦比亚琼脂上抑制作用消失。从同一患者中分离出39株“需氧菌”。所测试属的菌株与先前从非苯丙酮尿症来源测试的菌株反应相似。此外,厌氧分离的大肠杆菌受到抑制,而粪链球菌培养物未受抑制,这证实了对相同物种的需氧分离非苯丙酮尿症培养物的检测结果。这些首次涉及β-2-t与厌氧菌的研究表明,在体内β-2-t治疗期间,肠道细菌种群预计变化不大。